Bedaquiline Dosing for Pott's Spine (Rifampicin-Resistant Spinal TB)
For rifampicin-resistant Pott's spine in adults, use bedaquiline 400 mg orally once daily for 2 weeks, followed by 200 mg three times weekly for the remaining 22 weeks (total 24 weeks), taken with food as part of a multi-drug regimen containing at least 4-5 effective drugs. 1
Dosing Regimen Details
The standard bedaquiline dosing for drug-resistant tuberculosis, including extrapulmonary manifestations like spinal TB, follows this schedule:
- Loading phase: 400 mg orally once daily × 14 days
- Maintenance phase: 200 mg orally three times weekly × 22 weeks
- Total duration: 24 weeks (6 months) 1
Critical administration requirement: Bedaquiline must be taken with food to optimize absorption 2, 3
Regimen Construction for Pott's Spine
While the evidence specifically addresses pulmonary MDR-TB, the same dosing applies to extrapulmonary disease including spinal TB. Recent case reports demonstrate successful treatment of drug-resistant tuberculous spondylitis using bedaquiline-containing regimens 4.
Build the regimen using WHO Group A drugs first 3:
- Bedaquiline (as above)
- Levofloxacin OR moxifloxacin (levofloxacin preferred for less QTc prolongation)
- Linezolid
Add at least one Group B drug 3:
- Clofazimine OR
- Cycloserine/terizidone
Total treatment duration for spinal TB: 18 months minimum for the full regimen, though bedaquiline itself is only given for 6 months 3. Case reports of drug-resistant spinal TB show successful outcomes with 12-18 months total treatment including 6 months of bedaquiline 4.
Critical Monitoring Requirements
Baseline assessments before starting bedaquiline 1:
- ECG to measure QTcF interval (contraindicated if >450 ms)
- Serum electrolytes: potassium, calcium, magnesium
- Liver function tests
- Renal function
Ongoing monitoring 1:
- ECG: After initial 2 weeks, then monthly throughout treatment
- Electrolytes (K, Ca, Mg): Monthly and whenever QTc prolongation detected
- Liver function tests: Monthly
- Discontinue bedaquiline if:
- QTcF >500 ms (confirmed on repeat)
- Clinically significant ventricular arrhythmia
- Syncope (obtain ECG immediately)
Special Populations
Adolescents ≥12 years and ≥33-34 kg: Use adult dosing 1, 5
Children <12 years: Insufficient evidence; use only on case-by-case basis with expert consultation given high mortality risk of untreated disease 1, 5
Pregnancy: Recent South African data show no significant differences in pregnancy outcomes except possibly low birthweight (45% vs 26%, p=0.034), though causality unclear. Treatment success was 71% vs 62% in bedaquiline-exposed vs non-exposed pregnant women 6. Use when benefits outweigh risks.
Drug Interactions - Critical Contraindications
Avoid concurrent use with 2:
- Strong CYP3A4 inducers (carbamazepine, rifampin) - accelerated metabolism reduces bedaquiline effect
- QT-prolonging drugs require extreme caution:
- Fluoroquinolones (already in regimen - monitor closely)
- Clofazimine (often in regimen - requires intensive ECG monitoring)
- Antiarrhythmics, antipsychotics, tricyclic antidepressants
- Azole antifungals >14 days
Levofloxacin is preferred over moxifloxacin when building the regimen due to less QTc prolongation 3.
Efficacy Data Supporting Use
Bedaquiline-containing regimens demonstrate superior outcomes 1:
- Treatment success: Adjusted OR 2.7-5.0 for success vs failure/relapse
- Mortality reduction: Adjusted OR 0.3 for death (12.6% vs 24.8% in South African cohort)
- Culture conversion: Significantly faster than non-bedaquiline regimens
Common Pitfalls to Avoid
Do not use bedaquiline as monotherapy or add as single drug to failing regimen - always part of combination therapy with minimum 4 effective drugs 1
Do not forget food requirement - absorption significantly enhanced with high-fat meals 2
Do not neglect electrolyte monitoring - hypokalemia, hypomagnesemia increase QTc prolongation risk 1
Do not combine multiple QT-prolonging agents without intensive monitoring - bedaquiline + fluoroquinolone + clofazimine all prolong QTc 2, 3
Avoid alcohol during bedaquiline treatment 2
Duration Beyond 6 Months
While standard bedaquiline duration is 24 weeks, use beyond 6 months may be considered when effective treatment cannot otherwise be provided, though this remains off-label 1, 6. For spinal TB specifically, continue other effective drugs for full 18-month course after bedaquiline completion 3, 4.